Cambio interim report Q2

Cambio reported Q2 2026 revenue of 371.6 MSEK, up 19.8% y/y (from 310.1 MSEK). Adjusted EBITDA rose to 37.0 MSEK (from 11.2 MSEK), expanding margins to ~10% from ~4% a year ago, driven mainly by the RSRG program progressing into its next implementation phase.

Analysis

This reads more like an operating-leverage reset than a pure demand story. If the improvement is coming from a structured execution program, the market will reward it only if the next 1-2 quarters show that the margin step-up is repeatable after implementation spend normalizes; otherwise, the current uplift is just a temporary efficiency pocket that can fade as rollout complexity rises.

The second-order winners are customers and adjacent vendors that plug into a cleaner care-delivery workflow, because lower admin friction usually expands budget room for software add-ons and services. The likely losers are weaker healthcare IT implementers and local incumbents that compete on project execution rather than product depth; a visible win here can increase Cambio’s future tender win-rate and raise switching costs, but it can also force price pressure across the peer set if procurement teams start demanding the same productivity uplift elsewhere.

Near term, the key risk is that the market extrapolates an EBITDA margin that is too high for too long. If rollout intensity ramps, working capital and support costs can re-accelerate within 1-3 months, which would quickly deflate the quality narrative. Over 6-18 months, sustained double-digit margins with stable growth would justify a higher-quality multiple; the thesis is falsified if margin slips back below ~8% or cash conversion lags the reported profit step-up.

Key Decisions for Investors

• No immediate direct trade without a listed ticker; keep this on watchlist and only turn constructive if the next 1-2 reports confirm >15% growth and >10% EBITDA margin with no working-capital drag.
• If expressing the theme via public proxies, prefer a long basket of healthcare workflow/software names versus generic IT services for the next 1-3 months; the best risk/reward is where recurring revenue can absorb implementation noise.
• Set a falsifier alert on any guidance that implies margin normalization: if EBITDA margin guidance falls back below ~8% or cash conversion weakens, fade the operating-leverage narrative rather than chase it.